SCHEDULE 13G/A: Laurence W. Lytton Discloses 3.5% Passive Stake in Biofrontera Inc.
Beneficial Ownership Disclosure
Laurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 3.5% of Biofrontera Inc.'s common stock as of March 31, 2025.
Summary
- Laurence W. Lytton, a U.S. citizen, has filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in Biofrontera Inc.
- As of March 31, 2025, Mr. Lytton beneficially owns 306,700 shares of Biofrontera Inc. Common Stock.
- This ownership represents 3.5% of the company's outstanding Common Stock.
- The percentage is calculated based on 8,873,932 shares of Common Stock outstanding as of March 19, 2025, as reported by Biofrontera Inc. in its Form 10-K filed on March 20, 2025.
- Mr. Lytton holds sole voting power and sole dispositive power over all 306,700 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter sentiment, indicating a neutral impact.
Positives
- The filing indicates a passive investment, with the reporting person certifying that the shares were not acquired to change or influence the control of Biofrontera Inc., suggesting stability in corporate governance.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine disclosure of an individual's passive equity stake and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical or dermatology sectors where Biofrontera Inc. operates.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant individual shareholder's stake and confirms the passive nature of the investment, which may contribute to perceived stability.
Key Dates
| Date | Description |
|---|---|
| 03/19/2025 | Date as of which 8,873,932 shares of Common Stock outstanding were reported in Biofrontera Inc.'s Form 10-K. |
| 03/20/2025 | Date Biofrontera Inc. filed its Form 10-K, reporting shares outstanding. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Biofrontera Inc., Laurence W. Lytton, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.